A multi-dose Phase 2/3 study of DCR-PHXC

Trial Profile

A multi-dose Phase 2/3 study of DCR-PHXC

Phase of Trial: Phase II/III

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs DCR PHXC (Primary)
  • Indications Primary hyperoxaluria
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 New trial record
    • 08 Mar 2018 According to a Dicerna Pharmaceuticals media release, the company expects to initiate this trial in the first quarter of 2019, pending positive POC data and regulatory approvals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top